These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2544209)

  • 1. Effects of malotilate treatment on alcoholic liver disease.
    Takase S; Matsuda Y; Yasuhara M; Takada A
    Alcohol; 1989; 6(3):219-22. PubMed ID: 2544209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis.
    Takase S; Takada A; Yasuhara M; Sato H; Matsuda Y
    Gastroenterol Jpn; 1988 Dec; 23(6):639-45. PubMed ID: 2851477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of malotilate on alcoholic liver injury in rats.
    Matsuda Y; Takada A; Yasuhara M; Sato H
    Alcohol Clin Exp Res; 1988 Oct; 12(5):665-70. PubMed ID: 3067613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-fibrotic effect of malotilate on liver fibrosis induced by carbon tetrachloride in rats.
    Igarashi S; Hatahara T; Nagai Y; Hori H; Sakakibara K; Katoh M; Sakai A; Sugimoto T
    Jpn J Exp Med; 1986 Oct; 56(5):235-45. PubMed ID: 3027433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive effect of malotilate on carbon tetrachloride-induced liver damage and collagen accumulation in the rat.
    Ala-Kokko L; Stenbäck F; Ryhänen L
    Biochem J; 1987 Sep; 246(2):503-9. PubMed ID: 2825640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognosis of patients with alcoholic liver disease. An international randomized, placebo-controlled trial on the effect of malotilate on survival.
    Keiding S; Badsberg JH; Becker U; Bentsen KD; Bonnevie O; Caballeria J; Eriksen J; Hardt F; Keiding N; Morgan M
    J Hepatol; 1994 Apr; 20(4):454-60. PubMed ID: 8051381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connective tissue metabolism and alcohol intake in alcoholic liver disease.
    Niemelä O; Risteli J; Blake JE; Risteli L; Compton KV; Orrego H
    Alcohol Alcohol Suppl; 1991; 1():351-5. PubMed ID: 1845562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis.
    Torres-Salinas M; Parés A; Caballería J; Jiménez W; Heredia D; Bruguera M; Rodés J
    Gastroenterology; 1986 May; 90(5 Pt 1):1241-6. PubMed ID: 3007261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of malotilate on chronic liver injury induced by carbon tetrachloride in the rat.
    Dumont JM; Maignan MF; Janin B; Herbage D; Perrissoud D
    J Hepatol; 1986; 3(2):260-8. PubMed ID: 3794306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of malotilate on ethanol-inhibited hepatocyte regeneration in rats.
    Takada A; Nei J; Tamino H; Takase S
    J Hepatol; 1987 Dec; 5(3):336-43. PubMed ID: 3429841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.
    Bührer M; Le Cotonnec JY; Wermeille M; Bircher J
    Eur J Clin Pharmacol; 1986; 30(4):407-16. PubMed ID: 3743616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive monitoring of oxidant stress in alcoholic liver disease.
    Pemberton PW; Smith A; Warnes TW
    Scand J Gastroenterol; 2005 Sep; 40(9):1102-8. PubMed ID: 16165720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of hepatic fibrosis by serum proline and amino-terminal type III procollagen peptide levels in alcoholic patients.
    Tanaka Y; Minato Y; Hasumura Y; Takeuchi J
    Dig Dis Sci; 1986 Jul; 31(7):712-7. PubMed ID: 3720468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.
    Nøjgaard C; Johansen JS; Christensen E; Skovgaard LT; Price PA; Becker U;
    J Hepatol; 2003 Aug; 39(2):179-86. PubMed ID: 12873813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of di-isopropyl 1,3 dithiol-2-ylidenemalonate (malotilate) on the hepatic changes induced by ethanol administration in the rat.
    Ryle PR; Chakraborty J; Thomson AD
    Biochem Pharmacol; 1988 Nov; 37(22):4341-51. PubMed ID: 3143367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum procollagen type III N-terminal peptides and laminin P1 peptide in alcoholic liver disease.
    Nouchi T; Worner TM; Sato S; Lieber CS
    Alcohol Clin Exp Res; 1987 Jun; 11(3):287-91. PubMed ID: 3307495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group.
    J Hepatol; 1993 Feb; 17(2):227-35. PubMed ID: 8445237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Differences in changes of two serum markers of hepatic fibrogenesis in acute hepatitis].
    Matsuda Y; Yasuhara M; Takada A
    Nihon Shokakibyo Gakkai Zasshi; 1987 Aug; 84(8):1631-8. PubMed ID: 2826851
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum markers for hepatic fibrosis in alcoholic liver disease: which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase?
    Tsutsumi M; Takase S; Urashima S; Ueshima Y; Kawahara H; Takada A
    Alcohol Clin Exp Res; 1996 Dec; 20(9):1512-7. PubMed ID: 8986196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Measurement of serum type III procollagen aminopeptide with RIA-gnost PIIIP coated tube: changes in patients with various alcoholic liver diseases after abstinence].
    Maruyama K; Okazaki I; Takagi T; Takahashi H; Okuyama K; Horie Y; Takagi S; Kohno H; Sato S; Ishii H
    Kaku Igaku; 1992 Feb; 29(2):151-7. PubMed ID: 1564787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.